Glutathione Metabolism-related Gene Signature Predicts Prognosis and Treatment Response in Low-grade Glioma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 May 31

PMID 38819225

Authors

Zaidong Deng

Jing Luo

Jing Ma

Youngnam N Jin

Yanxun V Yu

Affiliations

Soon will be listed here.

Abstract

Cancer cells can induce molecular changes that reshape cellular metabolism, creating specific vulnerabilities for targeted therapeutic interventions. Given the importance of reactive oxygen species (ROS) in tumor development and drug resistance, and the abundance of reduced glutathione (GSH) as the primary cellular antioxidant, we examined an integrated panel of 56 glutathione metabolism-related genes (GMRGs) across diverse cancer types. This analysis revealed a remarkable association between GMRGs and low-grade glioma (LGG) survival. Unsupervised clustering and a GMRGs-based risk score (GS) categorized LGG patients into two groups, linking elevated glutathione metabolism to poorer prognosis and treatment outcomes. Our GS model outperformed established clinical prognostic factors, acting as an independent prognostic factor. GS also exhibited correlations with pro-tumor M2 macrophage infiltration, upregulated immunosuppressive genes, and diminished responses to various cancer therapies. Experimental validation in glioma cell lines confirmed the critical role of glutathione metabolism in glioma cell proliferation and chemoresistance. Our findings highlight the presence of a unique metabolic susceptibility in LGG and introduce a novel GS system as a highly effective tool for predicting the prognosis of LGG.

References

Jooma R, Waqas M, Khan I . Diffuse Low-Grade Glioma - Changing Concepts in Diagnosis and Management: A Review. Asian J Neurosurg. 2019; 14(2):356-363. PMC: 6516028. DOI: 10.4103/ajns.AJNS_24_18. View

Ozair A, Bhat V, Alisch R, Khosla A, Kotecha R, Odia Y . DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. Cancers (Basel). 2023; 15(4). PMC: 9954183. DOI: 10.3390/cancers15041342. View

Shu C, Li Q . Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. Crit Rev Oncol Hematol. 2020; 151:102965. DOI: 10.1016/j.critrevonc.2020.102965. View

Quail D, Joyce J . The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017; 31(3):326-341. PMC: 5424263. DOI: 10.1016/j.ccell.2017.02.009. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

Stupp R, Brada M, van den Bent M, Tonn J, Pentheroudakis G . High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii93-101. DOI: 10.1093/annonc/mdu050. View

Drew R, Miners J . The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem Pharmacol. 1984; 33(19):2989-94. DOI: 10.1016/0006-2952(84)90598-7. View

Anderton B, Camarda R, Balakrishnan S, Balakrishnan A, Kohnz R, Lim L . MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. EMBO Rep. 2017; 18(4):569-585. PMC: 5376764. DOI: 10.15252/embr.201643068. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

10.

Pouratian N, Schiff D . Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010; 10(3):224-31. PMC: 2857752. DOI: 10.1007/s11910-010-0105-7. View

11.

Wang Y, Ye S, Wu D, Xu Z, Wei W, Duan F . Identification, and Experimental and Bioinformatics Validation of an Immune-Related Prognosis Gene Signature for Low-Grade Glioma Based on mRNAsi. Cancers (Basel). 2023; 15(12). PMC: 10296549. DOI: 10.3390/cancers15123238. View

12.

Kennedy L, Sandhu J, Harper M, Cuperlovic-Culf M . Role of Glutathione in Cancer: From Mechanisms to Therapies. Biomolecules. 2020; 10(10). PMC: 7600400. DOI: 10.3390/biom10101429. View

13.

Tan Y, Li Y, Yan T, Xu Y, Liu B, Yang J . Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma. Front Immunol. 2021; 11:606164. PMC: 7779629. DOI: 10.3389/fimmu.2020.606164. View

14.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

15.

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister S . Glioma. Nat Rev Dis Primers. 2016; 1:15017. DOI: 10.1038/nrdp.2015.17. View

16.

Sun F, Lv H, Feng B, Sun J, Zhang L, Dong B . Identification of natural killer cell-related characteristics to predict the clinical prognosis and immune microenvironment of patients with low-grade glioma. Aging (Albany NY). 2023; 15(13):6264-6291. PMC: 10373982. DOI: 10.18632/aging.204850. View

17.

Chen X, Song E . Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018; 18(2):99-115. DOI: 10.1038/s41573-018-0004-1. View

18.

Louw D, Bose R, Sima A, Sutherland G . Evidence for a high free radical state in low-grade astrocytomas. Neurosurgery. 1997; 41(5):1146-50; discussion 1151. DOI: 10.1097/00006123-199711000-00025. View

19.

van den Bent M . Thirty years of progress in the management of low-grade gliomas. Rev Neurol (Paris). 2023; 179(5):425-429. DOI: 10.1016/j.neurol.2023.03.001. View

20.

Carabenciov I, Buckner J . Controversies in the Therapy of Low-Grade Gliomas. Curr Treat Options Oncol. 2019; 20(4):25. DOI: 10.1007/s11864-019-0625-6. View